Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | BRS3 | P32247 | 1/20 | 0.44 |
| ▸ | ATP1A1 | P05023 | 7/20 | 0.43 |
| ▸ | ATP1B1 | P05026 | 7/20 | 0.43 |
| ▸ | ATP1A3 | P13637 | 7/20 | 0.43 |
| ▸ | ATP1B2 | P14415 | 7/20 | 0.43 |
| ▸ | ATP4A | P20648 | 7/20 | 0.43 |
| ▸ | ATP1A2 | P50993 | 7/20 | 0.43 |
| ▸ | ATP4B | P51164 | 7/20 | 0.43 |
| ▸ | ATP1B3 | P54709 | 7/20 | 0.43 |
| ▸ | FXYD2 | P54710 | 7/20 | 0.43 |
| ▸ | ATP1A4 | Q13733 | 7/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10335251 | 0.91 | CYP1A2 (0.64) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8554015 | 0.90 | CYP2C9 (0.61) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9834850 | 0.90 | CYP3A4 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8503506 | 0.89 | CYP2C9 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8130091 | 0.89 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10580404 | 0.89 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8503277 | 0.88 | CYP2C9 (0.61) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9526970 | 0.87 | CYP2D6 (0.68) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9026559 | 0.87 | CYP2C9 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10965135 | 0.87 | CYP2D6 (0.65) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513870-A4 | CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL IN TREATING CYSTIC FIBROSIS AND METHODS AND PRODUCTS FOR DETECTING AND/OR IDENTIFYING SAME | CHILDRENS HOSP MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050158747-A1 | CFTR modifier genes and expressed polypeptides useful in treating cystic fibrosis and methods and products for detecting and/or identifying same | CHILDREN'S HOSPITAL MEDICAL CENTER | 2005-07-21 | — | — | US | claimed |
| EP-1513870-A2 | CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL IN TREATING CYSTIC FIBROSIS AND METHODS AND PRODUCTS FOR DETECTING AND/OR IDENTIFYING SAME | Children's Hospital Medical Center (US) | 2005-03-16 | — | — | EP | claimed |
| WO-2003102140-A2 | CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL IN TREATING CYSTIC FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | claimed |
| US-6159968-A | Activation of chloride channels for correction of defective chloride transport | UNIVERSITY OF CINCINNATI (US) | 2000-12-12 | — | — | US | claimed |
| US-4472409-A | ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-09-18 | — | — | US | claimed |
| EP-0080602-A1 | Substituted benzimidazoles, process for their preparation, their use and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1983-06-08 | — | — | EP | claimed |
| US-7524837-B2 | Benzotriazapinone salts and methods for using same | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-7105558-B2 | Gastrin and cholecystokinin receptor lignads (iv) | THE JAMES BLACK FOUNDATION LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| EP-1513870-A4 | CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL IN TREATING CYSTIC FIBROSIS AND METHODS AND PRODUCTS FOR DETECTING AND/OR IDENTIFYING SAME | CHILDRENS HOSP MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006051312-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| WO-2001085704-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (IV) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085724-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085167-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PROTON PUMP INHIBITORS AND GASTRIN/CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085723-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| US-6159968-A | Activation of chloride channels for correction of defective chloride transport | UNIVERSITY OF CINCINNATI (US) | 2000-12-12 | — | — | US | disclosed |
| US-4472409-A | ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-09-18 | — | — | US | disclosed |
| EP-0080602-A1 | Substituted benzimidazoles, process for their preparation, their use and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1983-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | CYP1A2 241/4885CYP3A4 196/4885CYP2D6 243/4885 |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | CYP1A2 241/4885CYP3A4 196/4885CYP2D6 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.